Highlights the importance of recognizing the heterogeneity of hypertrophic cardiomyopathy to direct individualized therapy.
HCM is a heterogeneous disease genotypically, phenotypically, pathophysiologically, clinically, and therapeutically. In decisions on the management of these patients, it is important to recognize this heterogeneity and to direct therapy at the predominant abnormalities.
Wigle et al. (Sun,) studied this question.